Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.
Latest From Pricing Debate
Agency hears from experts on whether PBMs and group purchasing organizations operate under misaligned incentives.
The nomination of a former drug industry executive to run HHS is obviously good news for the biopharma sector, but it does not mean that HHS will do nothing about drug prices. On the contrary, it may make some high-profile action against pricing outliers all but inevitable.
Outcomes-based managed entry agreements designed to help ensure access to expensive new medicines are not sustainable and have so far failed to provide a solution to the problem of funding costly innovative drugs, according to Ad Schuurman from ZIN, the Dutch National Healthcare Institute.
The Pharmaceutical Research and Manufacturers of America says the US Centers for Medicare and Medicaid Services should not itself initiate experiments with value-based payment approaches. Any demonstrations led by agency's CMMI should focus on "holistic" approaches to health costs.
CMS outlines possible approach to point-of-sale rebates in Medicare Part D, recognizing that using rebates to lower cost sharing for 'many' would increase premiums for all.
Data and intelligence will drive revolutionary changes in healthcare, and today's power brokers will need to adapt. Viren Mehta, founding partner of Mehta Partners LLC, considers how business consolidation in the complex US pharma market reflects the race to tap as yet under-exploited data troves, and how the resulting exploitation of those data may benefit a broader set of stakeholders.
Concerns with promoting competition and reducing consumers' 'pain in the pocketbook' are key tenets of the Trump Administration's approach to lowering prescription drug pricing, Grogan says.
Further evidence of the impact of pricing pressure in the US was provided when Sun Pharma reported a sharp fall in profits in Q2 (although it beat the expectations of some analysts). Sun also expects a delay in EU approval for its late stage psoriasis asset, tildrakizumab, but US approval timelines appear unchanged, at least for now.
Insurance practices are a big driver of drug pricing problems, according to Azar, a former Lilly exec who spent six years at HHS under George W. Bush, providing him valuable experience in department operations.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.